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Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, 
there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which 
seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to 
determine the prevalence of anti-HeV antibodies, acute hepatitis e, resolved hepatitis e, and exposure 
to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological 
characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy 
controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used 
for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected 
patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved 
hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find 
any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-
coinfected patients with CD4 T-cells <350 cells/mm3 had higher prevalence for anti-HeV IgG antibodies, 
resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/
mm3 (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in 
Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; 
particularly patients with CD4+t-cells <350 cells/mm3.
Hepatitis E virus (HEV) is transmitted by the fecal-oral route (contaminated water/food transmission), causes 
self-limiting hepatitis in humans without significant clinical implications in most cases, and is responsible for 
hepatitis E outbreaks worldwide1. HEV is the most common cause worldwide of acute viral hepatitis with an 
estimated prevalence of 20 million, with 3.3 million symptomatic cases and 44,000 deaths per year2. In Europe, 
HEV infection has been described as an emergent viral hepatitis in the last years3, with seroprevalences rang-
ing from 0.6 to 52.2%, as showed by a recent meta-analysis. In acute HEV infection, anti-HEV IgM antibodies 
are detected at the time of clinical onset (3–4 days from the onset of jaundice) and remain detectable for 3–12 
months. Anti-HEV IgG antibodies appear shortly after the IgM antibody response and persist for years4.
HEV prevalence in HIV-infected patients from European countries is from 0.95 to 26%, depending on the 
geographical location and study population. These rates are similar or higher than in the general population1,2,5, 
particularly for those with low CD4+ T-cell counts6. In this context, HEV seroprevalence ranged from 9% to 
26% in Spanish HIV-infected patients7–13. Therefore, HEV has emerged as a relevant pathogen for HIV-infected 
patients, mainly ones with low CD4+ T-cell counts or immunosuppression due to solid organ or bone marrow 
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transplant6. In this regard, HIV-infected patients coinfected with HEV constitute a high-risk population for devel-
oping chronic hepatitis and the rapid progression of liver disease, but it is poorly understood in HIV-infected 
patients6.
Around 2.3 million subjects worldwide are infected with both human immunodeficiency virus (HIV) and 
hepatitis C virus (HCV)14. There is little data on HEV infection in HIV/HCV-coinfected individuals with 
advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease1. 
Therefore, HIV/HCV-coinfected individuals constitute a population of particular interest since they have chronic 
hepatitis C with different stages of liver disease and a deregulated immune response that increases depending on 
the severity of liver disease15.
In this study, we aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hep-
atitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and 
epidemiological characteristics.
Results
patients. The characteristics of the HIV/HCV-coinfected patients are shown in Table 1. Overall, the median 
age was 49 years, 76.8% were males, 49.7% had high alcohol intake, 79.1% acquired HIV by intravenous drug use, 
29.1% had prior AIDS-defining conditions, and 98% were on combination antiretroviral therapy. Furthermore, 
19.4% had CD4+ T-cell <350 cells/mm3, 13.8% had values of HIV RNA >50 copies/mL, 49.5% were cirrhotic, 
71.1% were HCV-GT1 and 70.9% had HCV RNA >850,000 IU/mL. Table 1 shows the characteristics of the two 
control groups. The healthy controls were negative for HIV, HCV, and HBV infection. The HIV-monoinfected 
patients without HCV and HBV infection had undetectable HIV viral load and CD4 + > 500 cells/mm3, and all 
subjects were infected with HIV bisexual transmission (14 heterosexual and 22 homosexual).
Concordance analysis between HEV ELISA and immunoblot assays. We tested the concordance 
between ELISA and Immunoblot techniques for the screening of anti-HEV IgM and IgG antibodies by Cohen’s 
kappa test (Table 2). We found a weak concordance for anti-HEV IgM antibodies (kappa coefficient between 
0 and 0.342) and moderate-good for anti-HEV IgG antibodies (kappa coefficient between 0.526 and 0.718). 
HIV-monoinfected patients and HIV/HCV-coinfected patients had the highest kappa coefficient values.
HeV infection status. The seroprevalences for antibodies against HEV and their clinical interpretation 
are shown in Table 3. HIV/HCV-coinfected patients showed the highest prevalence of IgG antibody against 
HEV,resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively), but no significant differ-
ences between groups were found. Additionally, HIV/HCV-coinfected patients and HIV-monoinfected patients 
had the highest prevalences of anti-HEV IgM antibody and acute hepatitis E, but no significant differences from 
healthy controls were found. Moreover, we did not find any sample positive for HEV-RNA indicating that no 
patient had the possibility of chronic hepatitis E.
Influence of immunological status in HEV screening. We found that HIV/HCV-coinfected patients 
with CD4 T-cells <350 cells/mm3 had a higher prevalence of anti-HEV IgG antibodies, resolved hepati-
tis E, and exposure to HEV than healthy controls (p = 0.012, p = 0.020, and p = 0.006; respectively) and HIV/
HCV-coinfected patients with CD4 T-cells ≥350 cells/mm3 (p = 0.034, p = 0.035, and p = 0.053; respectively) 
(Fig. 1; full description in Supplementary Table 1). Finally, significant differences in other analyzed epidemiolog-
ical and clinical characteristics were not found (data not shown).
Discussion
In this work the main findings were: a) the concordance between ELISA and immunoblot assays was weak for 
anti-HEV IgM antibody and moderate-good for anti-HEV IgG antibody detection, making the confirmation test 
(immunoblot) necessary for HEV antibody screening in order to have comparable data between cohorts; b) HIV/
HCV-coinfected patients had a high prevalence (>15%)of anti-HEV IgG antibodies, resolved hepatitis E, and 
exposure to HEV; and (c) HIV/HCV-coinfected patients with CD4+ T-cells <350 cells/mm3 showed a higher 
prevalence (>25%) for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than patients with 
CD4+ T-cells >350 cells/mm3 and healthy controls. However, we did not find any relationship between HEV 
seroprevalence and the markers of liver disease, and no patient with a possible chronic HEV infection was found 
either.
There is limited data on HEV infection in HIV/HCV-coinfected patients, despite the fact that numerous stud-
ies have been published on HIV-infected patients5. In Spain there are several published works7–13 limited to a 
geographical area and presenting limited data in HIV/HCV-coinfected patients. This fact may lead to variability 
in HEV prevalence, as has already been demonstrated16. According to the World Health Organization and the 
European Centre for Disease Prevention and Control, HEV infection information for focused action is needed, 
particularly for those subjects considered as risk groups, such as patients with preexisting liver disease and immu-
nocompromised status17,18. In this sense, our study contributes information on the HEV prevalence in a popula-
tion of HIV/HCV-coinfected patients, of which 50% had cirrhosis and around 25% LSM >25 kPa (patients with 
high risk of clinical progression).
In our study we found disagreements between two serological techniques used for the determination of 
anti-HEV IgM and IgG antibodies (ELISA vs. immunoblot), reinforcing previous reports on the difficulties in 
HEV diagnosis4. These discrepancies were higher in anti-HEV IgM antibodies than anti-HEV IgG antibodies. The 
cause of this discordance is poorly understood, but the genetic variability of HEV and the differences in the anti-
gens used for HEV diagnosis could explain some of these differences, as well as the lack of a reliable gold stand-
ard that would provide confidence about a true “positive” or “negative” result4. In other studies, cross-reactivity 
in anti-HEV serology tests has been described when there are infections with Epstein–Barr virus (EBV) and 
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Cytomegalovirus (CMV)19,20, possibly due to reactive anti-HEV IgM antibodies generated by polyclonal acti-
vation of B-cells during acute human herpesviruses infections19,20. Moreover, the ELISA uses a selection of 
recombinant antigens with a determined conformation, which are not usually optimized, so these kits have high 
sensitivity but less specificity, resulting in an increase in the false positive rate4. However, this problem may be 
avoided by an immunoblot assay for the capture of IgM specific for HEV, since this assay tends to be more specific 
and thus can provide confirmation for the true positives4.
The serological diagnosis of HEV infection is not standardized, and commercially available assays show vari-
ability in specificity and sensitivity4. Thus, the HEV seroprevalence in the same cohort could vary when different 
assays are used, affecting the interpretation of the data. This fact makes it difficult to compare data from different 
studies based on the results of different assays5. In our study, we found that the seroprevalence of IgM and IgG 
antibodies against HEV in HIV/HCV-coinfected patients was higher than previous reports in the general Spanish 
Healthy controls HIV-monoinfected patients HIV/HCV-coinfected patients
No. 30 36 198
Age (years) 50.5 (47–53) 50 (46–52) 49 (46–52)
Gender (male) 15 (50.0%) 23 (63.9%) 152 (76.8%)
BMI (kg/m2) 24.97 (23.0–27.5) 25.28 (23.5–26.67) 24.39 (21.85–26.93)
BMI ≥ 25 (kg/m2) 13 (48.1%) 19 (54.3%) 83 (43.5%)
High alcohol intake — 1 (3.4%) 98 (49.7%)
HIV acquired by IVDU — 0 (0%) 155 (79.1%)
Prior AIDS — 12 (33.3%) 57 (29.1%)
Years since HIV infection — — 22 (18–26)
Years since HCV diagnosis — — 21 (17–23)
Previous HCV therapy (IFNα + rib) — 0 (0.0%) 90 (45.7%)
Antiretroviral therapy — 36 (100%) 192 (98.0%)
   Non-treated — 0 (0.0%) 5 (2.6%)
   PI-based — 8 (22.2%) 30 (15.4%)
   2NRTI + II-based — 4 (11.1%) 44 (22.6%)
   2NRTI + PI-based — 0 (0.0%) 39 (20.0%)
   2NRTI + NNRTI-based — 21 (58.3%) 61(31.3%)
   Others — 3 (8.30%) 16 (8.20%)
   HIV markers —
   Nadir CD4+ T-cells — 210 (114–343) 165 (84–250)
   Nadir CD4+ T-cells <200 cells/mm3 — 13 (39.4%) 117 (62.9%)
   CD4+ T-cells — 832 (685–1045) 527 (384–792)
   CD4+ T-cells <350 cells/mm3 — 0 (0.0%) 38 (19.4%)
   HIV-RNA >50 copies/mL — 0 (0.0%) 27 (13.8%)
HCV markers — —
   HCV genotype (N = 197) — —
   1 — — 140 (71.1%)
   2 — — 4 (2.0%)
   3 — — 35 (17.8%)
   4 — — 18 (9.1%)
Log10 HCV-RNA (IU/mL) — — 6.38 (5.84–6.77)
   HCV-RNA >850.000 IU/mL — — 157 (80.9%)
Non-invasive fibrosis indexes — —
   FIB-4 1.08 (0.85–1.21) 1.05 (0.88–1.34) 2.42 (1.51–4.04)
   FIB-4 >3.25 0 (0%) 0 (0%) 61 (32.3%)
LSM (kPa)
   F0-F1-F2-F3 (<12.5 kPa) — — 100 (50.5%)
   F4 (12.5–25 kPa) — — 52 (26.3%)
   F4 (25–40 kPa) — — 28 (14.1%)
   F4 (>40 kPa) — — 18 (9.1%)
Table 1. Clinical and epidemiological characteristics of the subjects includes in the study. Statistics: Values 
expressed as absolute number (percentage) and median (interquartile range). Abbreviations: HCV, hepatitis C 
virus; HCV-RNA, HCV plasma viral load; HIV-1, human immunodeficiency virus type 1; LSM, liver stiffness 
measure; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug user; AIDS, acquired immune deficiency 
syndrome; IFNα + rib, interferon-alpha plus ribavirin; NNRTI, non-nucleoside analogue HIV reverse 
transcriptase inhibitor; NRTI, nucleoside analogue HIV reverse transcriptase inhibitor; PI, protease inhibitor; 
II, integrase inhibitor; FIB-4: noninvasive test for liver fibrosis based on AST/ALT ratio and platelet count.
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population10,19,21,22, people living with HIV8,10,12,13, and other reports on HIV/HCV-coinfected patients8. And our 
seroprevalence data was higher even though most of the works did not include anti-HEV antibody confirmation 
by immunoblot, which likely would have reduced their seroprevalence data further. The study of Pineda et al. 
had a prevalence of 26% in HIV-infected patients, but this data was obtained without confirmation by immunob-
lot11. Moreover, our prevalence data in HIV/HCV-coinfected patients were also higher than previous reports of 
European people living with HIV5.
Levels of CD4+ T-cells in peripheral blood seem to be the most widely associated risk factor for HEV infec-
tion in HIV-infected patients6,23,24, although there are also articles that this association does not find25. The CD4+ 
T-cell counts reflect the level of immune suppression; and when CD4+ T-cells fall below 350 cells/μL, the risk of 
death, AIDS, and/or non-AIDS-defining conditions increases26–29. In our study, HIV/HCV-coinfected patients 
with CD4+ T-cells <350 cells/mm3 had a higher prevalence of anti-HEV IgG antibodies, resolved hepatitis E, and 
exposure to HEV than healthy controls and HIV/HCV-coinfected patients with CD4+ T-cells ≥350 cells/mm3. 
There is no clear explanation for this finding. One would think that subjects with CD4+ T-cells <350 cells/mm3 
No IgM anti-HEV Ab. Kappa p-value IgG anti-HEV Ab. Kappa p-value
Healthy controls 30 0/6 (0%) 0.001 0.006 2/5 (40%) 0.526 0.001
HIV-monoinfected patients 36 3/11 (27.3%) 0.342 <0.001 4/7(57.1%) 0.682 <0.001
HIV/HCV-coinfected patients 198 10/42 (23.8%) 0.330 <0.001 38/59 (64.4%) 0.718 <0.001
All subjects 264 13/59 (22.0%) 0.305 <0.001 44/71 (62.0%) 0.704 <0.001
Table 2. Summary of concordances between ELISA and immunoblot assays for IgM and IgG against HEV 
in the two control groups (healthy controls and HIV-monoinfected patients) and HIV/HCV-coinfected 
patients. Statistics: Values expressed as immunoblot positive/ELISA positive (%). P-values were calculated 





Ab. Acute hepatitis E Resolved hepatitis E Exposure to HEV
Healthy controls 0 (0%) 2 (6.7%) 0/30 (0%) 2/30 (6.7%) 2/30 (6.7%)
HIV-monoinfected patients 3 (8.3%) 4 (11.1%) 3/36 (8.3%) 3/36 (8.3%) 6/36 (16.7%)
HIV/HCV-coinfected patients 10 (5.1%) 38 (19.2%) 10/198 (5.1%) 34/198 (17.2%) 44/198 (22.2%)
p-value (HC vs. HIV) 0.505 0.845 0.514 0.760 0.389
p-value (HC vs. HIV/HCV) 0.710 0.127 0.721 0.230 0.082
p-value (HIV vs. HIV/HCV) 0.692 0.295 0.692 0.277 0.560
Table 3. Frequencies of immunoglobulins against HEV and clinical outcomes in the two control groups 
(healthy controls and HIV-monoinfected patients) and HIV/HCV-coinfected patients. Statistics: Values 
expressed as number of cases (%). P-values were calculated by chi-squared test or Fisher’s exact test as 
required. Abbreviations: HEV, hepatitis E virus; HC, healthy controls; HCV, hepatitis C virus; HIV-1, human 
immunodeficiency virus type 1.
Figure 1. Summary of (A) immunoblot assay for IgM and IgG and (B) clinical outcomes against hepatitis E 
virus in HIV/HCV-coinfected patients according to CD4+ T-cell status. Statistics: Values expressed as number 
of cases (%). P-values were calculated by chi-squared test or Fisher’s exact test as required.
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could have a worse immune response with lower titers of anti-HEV IgG antibodies, which could increase the false 
negative rate. However, we found higher seroprevalence of anti-HEV IgG antibodies in this subgroup of patients, 
which seems to indicate that CD4+ T-cells <350 cells/mm3 may predispose one to HEV infection. Moreover, 
this last explanation is not entirely clear since we found similar prevalence of anti-HEV IgM antibodies and acute 
hepatitis E in both groups of HIV/HCV-coinfected patients. Regarding this, we should not forget the possibility of 
false positives for anti-HEV IgM antibodies due to other concomitant infections19,20, as discussed above.
The detection of HEV-RNA is always recommended, but we did not find any sample with HEV-RNA in 
patients with anti-HEV IgM or IgG antibodies. Therefore, we could not confirm the HEV replication in any 
patient with acute hepatitis E. We also did not find any patient with a possible chronic hepatitis E since no study 
subject had both anti-HEV IgG antibodies and HEV-RNA in plasma. A possible explanation for this data is the 
temporary viremia of short duration during acute HEV infection with again time prior to the peak of antibodies 
against HEV4. In fact, most of the epidemiological studies published have reported very low numbers of positive 
results for HEV-RNA and chronic hepatitis E in healthy donors5,25 and HIV-infected patients8,9,11,12,25. Scotto et 
al. found a slightly higher frequency of chronic hepatitis HEV was present in subjects co-infected with HCV25. 
Despite this, HEV-RNA testing might offer an advantage in immunosuppressed patients with a worse antibody 
response to HEV4, although our HIV/HCV-coinfected patients did not have severe immunosuppression (CD4+ 
counts <200 cells/mm3).
Finally, we did not find any significant association between HEV seroprevalence and biomarkers of liver dis-
ease (LSM, liver stiffness, stages of liver fibrosis, and abnormal plasma liver enzymes), as previously suggested13,20.
This could represent an added difficulty for the use of these markers for HIV/HCV-coinfected patients with HEV 
infection.
Limitations of study. Firstly, this is a cross-sectional study with a limited number of patients in some of 
the study groups, which could result in a lack of uniformity and limit the possibility of finding significance. 
Secondly, we may have introduced a selection bias since the selection of patients from GESIDA 3603b was done 
with set criteria for starting HCV treatment according to guidelines in 2012–2014(e.g., CD4+ cell counts >200 
cells/mm3, controlled HIV replication, and proper treatment adherence). Thirdly, this study was performed in 
HIV/HCV-coinfected patients and it would be also interesting to analyze a group of HCV-monoinfected patients 
as a control group to compare HEV prevalences, but we did not have access to a cohort of HCV-monoinfected 
patients. Besides, it lacked patients with decompensated cirrhosis to compare the HEV prevalence with other 
fibrosis stages.
Conclusions. In conclusion, HIV/HCV-coinfected patients in Spain had high prevalences of IgG against 
HEV, resolved hepatitis E, and exposure to HEV as confirmed by immunoblot; in particular, patients with CD4+ 
T-cells <350 cells/mm3. Our data suggest the need to increase HEV surveillance to know the real magnitude of 
HEV infection and its clinical implications in HIV/HCV-coinfected patients.
patients and Methods
Patients and Study design. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 
from whom samples were collected from February 2012 to February 2014 from the cohort of “Grupo de Estudio 
del SIDA” (GESIDA 3603b study), and two control groups (30 healthy controls and 36 HIV-monoinfected 
patients). HIV/HCV-coinfected patients were candidates to start HCV therapy with peg-IFN-α/ribavirin or 
peg-IFN-α/ribavirin/direct-acting antivirals (DAAs) from 14 different institutions in Spain (see Appendix). A 
detailed description of the GESIDA 3603b study was previously reported15.
The study was conducted according to the Declaration of Helsinki, and patients gave their written informed 
consent to participate. The study cohort received the approval of the ethics committees of the participating 
centers. The Institutional Review Board and the Committee for Ethical Research (CEI) of the Instituto de Salud 
Carlos III (ISCIII) also approved the study.
Clinical data. The information of each patient was collected from medical records, as we have previously 
described15. All information was recorded using an online form in a shared database, which included all demo-
graphic, clinical, virological and laboratory data.
A liver stiffness measurement (LSM) was performed by transient elastography (FibroScan®, Echosens, Paris, 
France), as we have previously described15. Patients were stratified according to the following LSM cutoffs: <7.1 
kPa (F0-F1), 7.1–9.4 kPa (F2; significant fibrosis), 9.5-12.4 kPa (F3; advanced fibrosis), 12.5 to 25 kPa (non-risk of 
bleeding varices), 25 to 40 kPa (risk of bleeding varices), and >40 kPa (risk of hepatic decompensation).
HEV antibodies assays. Plasma samples were collected at the Spanish HIV HGM BioBank and stored at 
−80 °C until use. Samples were tested for HEV antibodies (IgM and IgG) by enzyme-linked immunosorbent 
assay (ELISA) using the Abbia HEV IgM and Abbia HEV IgG kits (AB Diagnostic Systems GmbH, Germany), 
following the manufacturer’s instructions, on an ETI-Max 3000 instrument (DiaSorin, Saluggia, Italy). All sam-
ples positive in the ELISA for IgM and IgG were subsequently confirmed using recomLine HEV IgG/IgM kit 
(MIKROGEN DIAGNOSTIK, Germany) using 20 µl per sample and following manufacturer’s instructions in an 
Auto-LiPA 48 device (INNOGENETICS®, Siemens Healthcare Diagnostic S.L.). We include a positive control 
(antibodies and RNA-HEV positives from an HEV-infected patient) in order to confirm the correct performance 
of the techniques and HEV detection.
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Viral RNA extraction. All samples with anti-HEV IgM/IgG antibodies were tested for HEV-RNA, which 
was extracted from 200 ml of plasma using a commercial DSP Virus/Pathogen mini kit (Qiagen, Hilden, 
Germany) in the QIAsymphony instrument(Qiagen, Hilden, Germany) and stored until use at −80 °C.
RT-PCR and Nested for HEV RNA detection. All samples from patients with anti-HEV IgM/IgG anti-
bodies were tested for HEV genome detection using a single-step retro-transcription and primary amplifica-
tion with the RT-PCR One-Step kit (Qiagen, Hilden, Germany) followed by nested PCR. A total of 5 µl of viral 
RNA extract was added to the RT-PCR mixture, which contained the following: 10 µl of 5X QIAGEN One-Step 
RT-PCR Buffer, 2 µl of dNTPs mix 10 mM, 0.25 µl of Rnase inhibitor 0.2 U/µl, 3 µl forward primer HEV1F 
5′-CCAYCAGTTYMTHAAGGCTC-3′ (10 µM) and reverse primer HEV1R 5′-TRCCAVCGCTGRACRTC-3′ 
(10 µM), 2 µl of QIAGEN One-Step RT-PCR Enzyme mix, and nuclease-free water to a final volume of 45 μl. All 
reagents except primers (Sigma), and RNase inhibitor (ROCHE) were supplied with the kit. Amplification was 
programmed as follows: 30 min at 50 °C; 15 min at 95 °C; 40 repetitive cycles of 35 sec at 94 °C, 45 sec at 52 °C and 
1 min at 72 °C; a final extension during 10 min at 72 °C.
Nested PCR was performed using 2 μl of the primary amplification product added to a mix containing 5 μl 
of 60% sucrose-0.08% cresol red, 5 μl of 10X PCR buffer 2w/15 mM MgCl2, 2 μl of 25 mM MgCl2, 1 μl of dNTPs 
10 mM, 2 μl of each primer at 10 μM (ORF1FN and ORFIRN, previously published19), 0.75 μl of expand HiFi 
enzyme, and RNase free water up to 48 μl. All reagents except primers, 60% sucrose-0.08% cresol red and dNTPs 
were supplied with the Roche Expand High Fidelity System kit (Roche). The thermal conditions were 4 min 
at 94 °C; 30 repetitive cycles of 35 sec at 94 °C, 45 sec at 48 °C, 45 sec at 72 °C with a final extension of 5 min at 
72 °C. Negative and positive controls were included in all amplification procedures. PCR products were visu-
alized on a 2% agarose gel containing 0.1 μl/ml of 10,000X SYBR safe (Invitrogen). Positive samples showed a 
HEV specific band size of ~172 bp. To avoid carryover contamination, standard precautions were taken. Different 
biosafety cabinets were used for extraction, mixing, RT-PCR and Nested PCR and pipetting was performed with 
aerosol-resistant tips. Moreover, amplicons were detected in a different room.
Clinical outcomes. The clinical interpretation of HEV screening was as follows: i) acute hepatitis E: a patient 
had acute hepatitis E when positive for anti-HEV IgM antibodies or both IgM and IgG, and/or HEV-RNA was 
detected; ii) resolved hepatitis E: a patient had resolved hepatitis E when only anti-HEV IgG antibodies were 
detected; and iii) exposure to HEV: a patient was exposed to HEV when acute or resolved hepatitis E was detected. 
This interpretation was made based on data confirmed by immunoblot since all patients positive for IgM came 
out negative for viral detection.
Statistical analysis. Analyses were performed using IBM SPSS Statistics for Windows, Version 21.0 (IBM 
Corp, Armonk, NY, USA) and OpenEpi (http://www.openepi.com/Menu/OE_Menu.htm)30. All p-values were 
two-tailed and statistical significance was defined as p < 0.05.
For the descriptive study, values were expressed as absolute number (percentage) and median (25th; 75th 
percentile). Categorical data and proportions were analyzed using the chi-squared test or Fisher’s exact test. 
Mann-Whitney test was used to compare data among independent groups. The inter-rater agreement or con-
cordance between serological techniques was measured by Cohen’s kappa coefficient.
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